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Abstract
 
The molecular basis of thymocyte negative selection, which plays a critical role in establishing
and maintaining immunological tolerance, is not yet resolved. In particular, the importance of
the death receptor subgroup of the tumor necrosis factor (TNF)-family has been the subject of
many investigations, with equivocal results. A recent report suggested that TRAIL was a criti-
cal factor in this process, a result that does not fit well with previous studies that excluded a role
for the FADD-caspase 8 pathway, which is essential for TRAIL and Fas ligand (FasL) signaling,
in negative selection. We have investigated intrathymic negative selection of TRAIL-deficient
thymocytes, using four well-established models, including antibody-mediated TCR/CD3 liga-
tion in vitro, stimulation with endogenous superantigen in vitro and in vivo, and treatment
with exogenous superantigen in vitro. We were unable to demonstrate a role for TRAIL sig-
naling in any of these models, suggesting that this pathway is not a critical factor for thymocyte
negative selection.
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Introduction
 
Intrathymic T cell development involves the differentiation
and selection of T cells that carry a TCR that is self-MHC
restricted but does not bind with high affinity to self-anti-
gen derived peptides presented by self-MHC molecules.
The processes that produce such a selected T cell repertoire
are called positive selection and negative selection respec-
tively (1, 2). Negative selection is central to the generation
of a self-tolerant T cell repertoire, and recent studies have
reiterated the importance of intrathymic negative selection
in the prevention of autoimmune disease (3–5). The phe-
nomenon of negative selection has always presented a par-
adox to immunologists, as it is mediated by the same
TCR/CD3 complex that governs positive selection and
CD4/CD8 lineage commitment and later in the life of a T
cell mediates activation and clonal expansion. Negative se-
lection is a differentiation stage-specific phenomenon, and
depending on the model system, may operate at the imma-
ture CD4
 
 
 
CD8
 
 
 
 double-positive stage of thymocyte dif-
ferentiation in the thymic cortex and/or at the later
CD3
 
 
 
CD4
 
 
 
CD8
 
 
 
or CD3
 
 
 
CD4
 
 
 
CD8
 
 
 
 stage when thy-
mocytes transit through the cortico-medullary junction (2).
Medullary thymocytes continue to differentiate and even-
tually reach a stage where they are beyond the window of
negative selection and are ready to migrate from the thy-
mus to peripheral lymphoid tissues. This transition is
thought to occur as these cells down-regulate the matura-
tion marker CD24 (heat stable antigen [HSA]), a very late
event in intrathymic T cell development (6).
The clearly distinct outcomes (deletion versus activation)
after TCR ligation in immature versus mature T cells may
reflect a change in the way these cells interpret signals from
their TCR, or alternatively, other possibilities are that ap-
optotic death may result from additional signals received at
the immature stage or absence of survival-promoting sig-
nals that are received only later in more differentiated cells.
The search for the apoptosis signaling pathway(s) in thy-
mocyte negative selection has been a long-term quest for T
cell immunologists. Mammals have two distinct apoptosis
signaling pathways (7), one regulated by pro- and antiapop-
totic members of the Bcl-2 protein family and the other ac-
tivated by ‘death receptors’ members of the TNF-R family
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with an intracellular death domain, and both have been im-
plicated in thymocyte negative selection. Three intracellu-
lar signaling factors have been clearly shown to be critical
for negative selection, being Nur-77/Nurr1/Nor1 tran-
scription factor family (8, 9) and the pro-apoptotic Bcl-2
family members BIM (4), and Bax plus Bak (10). Many
studies have investigated whether death receptors, includ-
ing: FAS, TNF, DR3, LT, LIGHT, and CD30 (for re-
views, see references 11–15), play a role in thymocyte neg-
ative selection. Evidence has been provided suggesting a
role for FAS at high but not low intensity TCR/CD3-
stimulation. This is, however, not supported by studies
showing that negative selection is intact in transgenic mice
lacking FADD or caspase-8 function due to expression of a
dominant-interfering mutant of FADD or the viral serpin
CrmA (16, 17). Recently, a critical role for the TNF family
member TNF-related apoptosis-inducing ligand (TRAIL)
was proposed, based upon studies using several in vitro and
in vivo models where negative selection was at least par-
tially impaired in TRAIL-deficient mice or in the presence
of blocking soluble TRAIL receptor, DR5 (18). This result
is also at odds with early results from FADD dominant neg-
ative and CrmA transgenic mice, as FADD and caspase-8
are essential for TRAIL-induced apoptosis. Even more
puzzling, it clearly contrasts with a previous study using
TRAIL inhibitors that indicated that negative selection of
mouse and human thymocytes was TRAIL-independent
(19). The reasons for these discrepancies are unclear, al-
though it was suggested that TRAIL might utilize an alter-
native (undefined) apoptosis signaling pathway that does
not involve FADD-caspase 8 but may activate Bim and
Bax/Bak (20).
We sought to investigate this problem using a range of
well-established negative selection models, including in
vitro TCR/CD3 ligation, in vivo and in vitro deletion of
endogenous superantigen reactive T cells, and in vitro
stimulation with the superantigen staphylococcal entero-
toxin B (SEB).
 
Materials and Methods
 
Mice.
 
Inbred BALB/c and C57BL/6 (B6) WT mice were
purchased from the Walter and Eliza Hall Institute. The TRAIL
gene-targeted mice were originally derived at Immunex Cor-
poration as described (18, 21) and bred at the Peter MacCal-
lum Cancer Centre: BALB/c TRAIL-deficient mice (BALB/c
TRAIL
 
 
 
/
 
 
 
) were 10 generations backcrossed to BALB/c and
C57BL/6 TRAIL-deficient (B6 TRAIL
 
 
 
/
 
 
 
) mice (5 generations
backcrossed to C57BL/6). Mice were used in all experiments un-
der specific pathogen-free conditions according to animal experi-
mental ethics committee guidelines. Mice were culled and their
thymus, spleen, axial, brachial, and inguinal lymph nodes re-
moved for analysis of cellularity and composition.
 
Fetal Thymic Organ Culture.
 
Fetal thymic lobes were isolated
from day 15 BALB/c WT and BALB/c TRAIL
 
 
 
/
 
 
 
 embryos and
cultured for 12 d in RPMI-1640 (Invitrogen/Life Technologies)
medium supplemented with 10% FCS (Commonwealth Serum
Laboratories [CSL]), 2 mM GlutaMAX, 100 IU/ml penicillin,
100 
 
 
 
g/ml streptomycin, 15 mM HEPES buffer (Invitrogen),
 
and 1 mM sodium pyruvate (Invitrogen) with or without 20 
 
 
 
g/
ml anti-mTRAIL mAb (N2B2; reference 22) and 10 
 
 
 
g/ml SEB
(Toxin Technology Co.). Lobes were cultured in groups of 2 per
well of a 6-well plate and medium was changed after 6 d. At the
end of culture, thymocytes were harvested from lobes, counted
and analyzed by flow cytometry.
 
Anti-CD3 Ligation In Vitro.
 
For in vitro analysis, thymocyte
suspensions were produced from E18 thymic lobes of BALB/c
and BALB/c TRAIL
 
 
 
/
 
 
 
 mice. Cells were cultured at a density of
10
 
6
 
 cells/ml, in DMEM medium supplemented with 10% FCS in
wells of a 96-well plate that had been coated overnight with
hamster anti–mouse CD3
 
 
 
 (145–2C11), anti-CD28 (37.51) mAb
(both from BD Biosciences), or PBS. 20 h later, proportions of
live and apoptotic cells were identified by staining with propid-
ium iodide (Sigma Aldrich) and annexin V-FITC (Roche). Live
cells were considered to be PI
 
 
 
 and annexin V-FITC
 
 
 
.
 
Immunofluorescence Staining and Flow Cytometric Analysis.
 
Thy-
mocytes, splenocytes, and lymph node cells were stained with
surface marker-specific mAbs including: anti-CD3-FITC (17A2),
anti-CD4-PerCP-Cy5.5 (RM4–5), anti-CD8
 
 
 
-PE (53–6.7), anti-
TCRV
 
 
 
3-biotin (KJ25), anti-TCRV
 
 
 
5.1/5.2-biotin (MR9–4),
anti-TCRV
 
 
 
6-biotin (RR4–7), anti-TCRV
 
 
 
8.1–8.2-biotin (MR5–2),
and anti-TCRV
 
 
 
11-biotin (RR3–15) (all BD Biosciences), in
the presence of anti-Fc
 
 
 
 receptor block CD16/32 (clone 2.4G2).
Biotinylated antibodies were detected with streptavidin-APC
(BD Biosciences). Analysis was performed on a FACSCalibur™
(Becton Dickinson).
 
Results
 
We first examined anti-CD3 plus anti-CD28 mAb-
induced apoptosis in vitro. E18 mice are a rich source of
DP immature thymocytes (90–95%), and these importantly
lack mature T cells that might upon TCR/CD3 ligation
release soluble factors that kill DP thymocytes indirectly.
Stimulation with anti-CD3 plus anti-CD28 mAbs killed
thymocytes from E18 WT BALB/c mice in a dose-depen-
dent manner as determined by staining with the vital dye
PI and FITC-coupled annexin V (Fig. 1), which detects
externalized phosphatidyl-serine, a hallmark of apoptotic
Figure 1. Thymocyte apoptosis in vitro. Thymocytes from BALB/c
and BALB/c TRAIL /  E18 mice were cultured in plates coated with
anti-CD3  (145–2C11) plus anti-CD28 (37.51) mAbs or PBS. Neutraliz-
ing anti-TRAIL antibodies were added to some of the cultures. After 20 h,
live and apoptotic cells were discriminated by staining with annexin
V-FITC plus propidium iodide and flow cytometric analysis. Data represent
mean and standard error of the mean for six BALB/c mice plus or minus
the addition of anti-mTRAIL mAb) or four BALB/c TRAIL /  mice.T
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cells. TRAIL-deficient (TRAIL
 
 
 
/
 
 
 
) BALB/c thymocytes
or blocking of TRAIL with a neutralizing antibody in cul-
tures of WT thymocytes afforded no protection at any of
the concentrations of anti-CD3/anti-CD28 mAbs used
(Fig. 1). The spontaneous death of thymocytes in culture
was also equivalent between WT and TRAIL
 
 
 
/
 
 
 
 mice.
Similar results were obtained in vitro when analyzing DP
thymocytes from adult BALB/c or C57BL/6 WT and
TRAIL
 
 
 
/
 
 
 
 mice (unpublished data).
The effect of TRAIL-deficiency was also examined in
fetal thymus organ culture (FTOC) (Fig. 2). Consistent
with previous reports, addition of SEB induced complete
deletion of CD3
 
high
 
 TCR V
 
 
 
8
 
 
 
 T cells in fetal thymus
lobes derived from BALB/c WT mice whereas TCRV
 
 
 
6
 
 
 
T cells, which do not respond to SEB, remained unaffected
(Fig. 2). Loss of TRAIL or addition of neutralizing anti-
TRAIL antibodies had no effect on SEB-induced deletion
of TCRV
 
 
 
8
 
 
 
 T cells (Fig. 2). T cells developing in FTOC
were also examined for the deletion of V
 
 
 
5
 
 
 
 T cells that is
caused by the endogenous superantigen mouse mammary
tumor virus (MMTV)9 presented by I-E
 
 
 
 class II MHC.
Also in this depletion process, lack of TRAIL or addition
of neutralizing anti-TRAIL antibodies afforded no protec-
tion against negative selection (Fig. 2).
Intrathymic deletion of developing T cells caused by en-
dogenous superantigens MMTV6 and MMTV9, was fur-
ther assessed in adult BALB/c mice. These endogenous su-
perantigens delete TCRV
 
 
 
3
 
 
 
 and TCRV
 
 
 
5
 
 
 
 T cells,
respectively, in mice that express the class II MHC antigen
(I-E). We examined the frequencies of TCRV
 
 
 
3
 
 
 
 and
TCRV
 
 
 
5
 
 
 
 T cells amongst CD4
 
 
 
 and CD8
 
 
 
 subsets in
thymus, spleens and peripheral lymph nodes (Fig. 3) in
BALB/c WT or BALB/c TRAIL
 
 
 
/
 
 
 
 mice by immunoflu-
orescent staining with TCRV
 
 
 
-specific mAbs and flow cy-
tometry. Similar deletion of T cells with these specificities
was observed in BALB/c WT and TRAIL
 
 
 
/
 
 
 
 mice, com-
pared with C57BL/6 mice (I-E
 
 
 
) where cells with these
specificities were not deleted (Fig. 3). As a control, we also
Figure 2. SEB-induced deletion of TCR
V 8  cells in FTOC. Thymic lobes from E15
mice were cultured for 12 d in the presence of
10  g/ml SEB plus or minus 20  g/ml anti-
mTRAIL mAb or an equivalent volume of
PBS. Thymocyte suspensions were isolated,
counted, and stained with antibodies to CD4,
CD8, CD3, and TCR V 8, V 6, or V 5. (A)
Histograms demonstrate expression of TCR
V 8, TCR V 6, or TCR V 5 on CD3high
thymocytes (CD4  or CD8 ) after incubation
with SEB or PBS; and (B) total cells per lobe
and TCR V 8 , V 6 , or V 5  cells as a per-
centage of CD3 CD4 CD8  and CD3 CD4 
CD8  thymocyte subsets. Mean and standard
error of mean were calculated from analysis of
six BALB/c TRAIL /  and eight BALB/c WT
thymic lobes each for both PBS and SEB treat-
ment.T
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showed that TCRV
 
 
 
6
 
 
 
 and TCRV
 
 
 
8
 
 
 
 T cells are not de-
leted in either BALB/c WT or TRAIL
 
 
 
/
 
 
 
 mice. Consis-
tent with an earlier report (18), the thymus of adult
TRAIL
 
 
 
/
 
 
 
 mice (2.19 
 
 
 
 0.14 
 
 
 
 10
 
8
 
) was slightly enlarged
compared with WT mice (1.77 
 
 
 
 0.04 
 
 
 
 10
 
8
 
; P 
 
  0.0127,
Mann Whitney), however there was no significant differ-
ence in spleen or lymph node cellularity between the
strains (unpublished data). The basis for this subtle differ-
ence is unclear, but does not appear to be due to impaired
negative selection.
Discussion
The role of TRAIL signaling in intrathymic negative se-
lection is controversial. Our data, using four separate mod-
els of thymocyte negative selection, has fallen clearly on the
side arguing that TRAIL is not required for this process.
Thus, we agree with earlier results by Simon et al. (19).
Moreover, our data fits well with results from Smith et al.
(17) and Newton et al. (16) demonstrating normal negative
selection of thymocytes lacking caspase-8 or FADD func-
tion. It is difficult to explain why our results are so distinct
from those recently published (18), which use TRAIL / 
mice from the same source and similar models for studying
negative selection. Lamhamedi-Cherradi et al. additionally
examined thymocyte apoptosis after anti-CD3 treatment in
vivo; however this form of apoptosis is known to be largely
TCR-independent, with a major role for TNF and gluco-
corticoid hormones (23, 24). Nevertheless, we also per-
formed such experiments and TRAIL was not critical for
deletion (unpublished data).
Careful analysis of at least some of the data in the
Lamhamedi-Cherradi et al. study reveals some uncertain-
ties—in particular, the proportions of TCRV 5  and
TCRV 11  T cells in peripheral lymphoid organs in
TRAIL-deficient mice are only slightly (albeit significantly)
increased. These T cells are deleted due to the presence of
MMTV9 presented by I-E as occurs in BALB/c mice. In
MMTV9  and I-E negative mice, such as C57BL/6, the
proportion of these cells is at least 10 times that detected in
BALB/c mice. The percentage of these cells in TRAIL-
deficient BALB/c mice is barely above the percentage in
control BALB/c mice, which indicates that at least for that
model, the impact of TRAIL in negative selection is rather
subtle at best. Perhaps the best results on MMTV9-medi-
ated deletion would have been obtained from SP thy-
mocytes, rather than DP thymocytes as presented (18).
Analysis of DP thymocytes is complicated by the fact that
most of these cells express only very low levels of cell sur-
face TCR  , and only the very latest stages of DP thy-
mocyte development are susceptible to MMTV-mediated
negative selection (25, 26). Thus, changes in TCRV  rep-
resentation in this population are far more difficult to de-
tect and less reliable than in SP thymocytes. Indeed, our
findings were that in BALB/c mice TCRV 5  T cells
were not dramatically under-represented in the DP thy-
mocyte population, in contrast to their clear deficiency at
the SP stage, which is consistent with the earlier study by
Hugo et al. (25). Furthermore, MMTV9 is able to mediate
significant deletion of TCRV 5  cells in C57BL/6 mice
(I-A , I-E ) and the proportion and number of these cells
is increased in BIM-deficient C57BL/6 mice (4) that are
known to have impaired negative selection. By contrast, as
no difference in the percentage of TCRV 5  cells was re-
ported in C57BL/6 TRAIL-deficient mice (18), this again
raises some concern over the extent to which TRAIL reg-
ulates negative selection. It will be interesting to further as-
sess intrathymic negative selection in mice lacking the
Figure 3. MMTV-6 and MMTV-9 induced deletion of TCR V 3 and V 5 T cells. Thymocytes, splenocytes, and lymph node cells were isolated
from 8-wk-old C57BL/6 (n   3), BALB/c (n   12), and BALB/c TRAIL /  mice (n   11). Cell suspensions were stained with antibodies to CD4,
CD8, CD3, and TCR V 3, V 5, V 6, or V 8. (A) Histograms demonstrate expression of TCR V 3, TCR V 5, TCR V 6, or TCR V 8 on CD4 
CD3high or CD8  CD3high thymocytes. (B) TCR V 3, TCR V 5, TCR V 6, or TCR V 8 cells as a percentage of CD3 CD4 CD8  and
CD3 CD4 CD8  subsets of thymocytes, splenocytes, and peripheral lymph node cells.T
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TRAIL death receptor (DR5) or TRAIL and additional
TNF family members.
BIM mutation leads to impaired negative selection of T
cells in mice and spontaneous development of autoimmune
glomerulonephritis (3). Mutation of autoimmune regulator
(AIRE) in mice also leads to a failure to delete organ-spe-
cific cells in the thymus and predisposes to a spectrum of
organ-specific autoimmune diseases in mice (5, 27) and hu-
mans (28). We have failed to reveal any signs of spontane-
ous autoimmunity, even in very old B6 TRAIL /  mice
( 550 d) and BALB/c TRAIL /  ( 300 d) mice, com-
pared with similarly aged syngeneic WT mice (unpublished
data). Similar peripheral lymph node and spleen cellularity
and composition, serum Ig levels, and pancreas, kidney,
and spleen architecture were detected in these aged mice.
While TRAIL-deficient mice may be more susceptible to
the induction of autoimmunity in certain experimental
models (29, 30), it remains unclear by what mechanism
TRAIL suppresses the induction of autoimmunity. Clearly,
disease induction in these models is complex and often in-
volves adjuvants that stimulate dendritic cells and innate
immune cell networks. The lack of any signs of autoimmu-
nity in aged TRAIL-deficient mice is further evidence that
TRAIL is not critical for maintaining self-tolerance, and is
dispensable for intrathymic negative selection.
In summary, while TRAIL may be functional on acti-
vated mature T cells and NK cells and may be capable of
suppressing induction of autoimmune disease, we have
shown in four different models that TRAIL is not critical
for intrathymic negative selection. Using both TRAIL-
deficient mice, and a powerful neutralizing anti–mouse
TRAIL mAb, we failed to detect an essential role for
TRAIL in T cell deletion in these systems. We are unable
to easily explain the basis of the discrepancies between our
results and those recently published, but in light of our data
and other studies supporting our results (19), we suggest
that the importance of TRAIL in intrathymic negative se-
lection is, at best, unclear and requires further investigation.
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